Study suggests probiotic strain affects I.B.S.
April 07, 2009
by Jeff Gelski
CLEVELAND — Preliminary data suggest the patented probiotic strain Bacillus coagulans GBI-30, 6086 may be a safe and effective option for the relief of abdominal pain and bloating for patients with irritable bowel syndrome (I.B.S.), according to study results published in the March issue of Postgraduate Medicine. Larger, extended trials are needed to verify the results.
The randomized, double-blind, parallel-group, placebo-controlled clinical trial involved 44 subjects. They received either a placebo or the probiotic strain once a day for eight weeks. They recorded self-assessments of the severity of I.B.S. symptoms every day for eight weeks. Improvements from baseline abdominal pain and bloating scores in the B. coagulans GBI-30, 6086 group were statistically significant for all seven weekly comparisons. In the placebo group, statistically significant improvements were achieved in the sixth week and in the eighth week.
"This study helps confirm that Bacillus coagulans is effective in I.B.S.," said Dr. Larysa Hun, M.D., author of the study. "A combination of Bacillus coagulans, Lactobacillus acidophilus and Streptococcus thermopilus was previously shown in a clinical trial to significantly improve I.B.S. symptoms, but it was not possible to determine what effect, if any, each strain has by itself."
Ganeden Biotech, Cleveland, offers the probiotic strain used in the study under the trademark name GanedenBC30.